Population Modeling of Tumor Kinetics and Overall Survival to Identify Prognostic and Predictive Biomarkers of Efficacy for Durvalumab in Patients With Urothelial Carcinoma
Open Access
- 15 December 2017
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 103 (4), 643-652
- https://doi.org/10.1002/cpt.986
Abstract
Durvalumab is an anti‐PD‐L1 monoclonal antibody approved for patients with locally advanced or metastatic urothelial carcinoma (UC) that has progressed after platinum‐containing chemotherapy. A population tumor kinetic model, coupled with dropout and survival models, was developed to describe longitudinal tumor size data and predict overall survival in UC patients treated with durvalumab (NCT01693562) and to identify prognostic and predictive biomarkers of clinical outcomes. Model‐based covariate analysis identified liver metastasis as the most influential factor for tumor growth and immune‐cell PD‐L1 expression and baseline tumor burden as predictive factors for tumor killing. Tumor or immune‐cell PD‐L1 expression, liver metastasis, baseline hemoglobin, and albumin levels were identified as significant covariates for overall survival. These model simulations provided further insights into the impact of PD‐L1 cutoff values on treatment outcomes. The modeling framework can be a useful tool to guide patient selection and enrichment strategies for immunotherapies across various cancer indications.Keywords
Funding Information
- MedImmune, the global R&D biologics arm of AstraZeneca
This publication has 30 references indexed in Scilit:
- Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial CarcinomaJournal of Urology, 2016
- Modeling and simulations relating overall survival to tumor growth inhibition in renal cell carcinoma patientsCancer Chemotherapy and Pharmacology, 2015
- A Review of Mixed‐Effects Models of Tumor Growth and Effects of Anticancer Drug Treatment Used in Population AnalysisCPT: Pharmacometrics & Systems Pharmacology, 2014
- Population pharmacokinetics and exposure–response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancerCancer Chemotherapy and Pharmacology, 2014
- Evaluation of Tumor Size Response Metrics to Predict Survival in Oncology Clinical TrialsClinical Pharmacology & Therapeutics, 2014
- PKPD Modeling of VEGF, sVEGFR‐2, sVEGFR‐3, and sKIT as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GISTCPT: Pharmacometrics & Systems Pharmacology, 2013
- Prognostic Model for Predicting Survival of Patients With Metastatic Urothelial Cancer Treated With Cisplatin-Based ChemotherapyJNCI Journal of the National Cancer Institute, 2013
- Tumor growth modeling from clinical trials reveals synergistic anticancer effect of the capecitabine and docetaxel combination in metastatic breast cancerCancer Chemotherapy and Pharmacology, 2011
- Elucidation of Relationship Between Tumor Size and Survival in Non-Small-Cell Lung Cancer Patients Can Aid Early Decision Making in Clinical Drug DevelopmentClinical Pharmacology & Therapeutics, 2009
- A general framework for modeling tumor-immune system competition and immunotherapy: Mathematical analysis and biomedical inferencesPhysica D: Nonlinear Phenomena, 2005